The combination of drug therapy with CD8+ T cell vaccines can have a synergistic affect when the immunogenicity of tumors can be enhanced, an example would be the administration of a chemotherapeutic such as drug 5-aza-2-deoxycitidine which increases tumor MHC class I expression, as well as some tumor antigens, enhancing survival in tumor bearing mice [53,54]. The gene discussed is CD8A; the disease is neoplasm.